Literature DB >> 7806369

Tumor necrosis factor (TNF)-dependent shedding of the p55 TNF receptor in a baboon model of bacteremia.

H Redl1, G Schlag, G R Adolf, B Natmessnig, J Davies.   

Abstract

We have tested the hypothesis that the tumor necrosis factor (TNF) plays a significant role in vivo in TNF receptor shedding and studied the release of TNF-binding protein 1 (TNF-BP1), the soluble fragment of the 55- to 60-kDa TNF alpha (TNF) receptor, in a baboon model of Escherichia coli bacteremia, using three different doses of bacteria in acute infection (8 h) experiments (n [animals] = 11) and a single dose in a subchronic infection (72 h) experiment. In the subchronic infection study, one group of animals (n = 6) was pretreated with a neutralizing murine monoclonal antibody to TNF (CB0006). Concentrations of TNF and TNF-BP1 in plasma were determined in specific, monoclonal antibody-based immunoassays. Untreated animals (n = 6) showed undetectable TNF concentrations (< 10 pg/ml at baseline), whereas TNF-BP1 levels in plasma were in the range of 2 ng/ml, similar to concentrations observed in humans. Infusion of bacteria resulted in a rapid, dose-dependent increase in plasma TNF concentrations that reached a maximal level after 2 h and returned to baseline within 6 h. TNF-BP1 concentrations also showed a dose-dependent increase to peak concentrations three- to fivefold above baseline within 2 h but, in contrast to TNF levels, remained significantly elevated for up to 48 h. In animals pretreated with antibody CB0006, circulating TNF was completely neutralized, and TNF-BP1 was significantly reduced. We conclude that TNF-BP1 is released in bacteremia and that release in vivo is partially dependent on the presence of TNF.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7806369      PMCID: PMC172991          DOI: 10.1128/iai.63.1.297-300.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  TNF and other cytokines in the metabolism of septic shock and cachexia.

Authors:  K J Tracey
Journal:  Clin Nutr       Date:  1992-02       Impact factor: 7.324

2.  Involvement of an Asn/Val cleavage site in the production of a soluble form of a human tumor necrosis factor (TNF) receptor. Site-directed mutagenesis of a putative cleavage site in the p55 TNF receptor chain.

Authors:  U Gullberg; M Lantz; L Lindvall; I Olsson; A Himmler
Journal:  Eur J Cell Biol       Date:  1992-08       Impact factor: 4.492

3.  Hyperdynamic sepsis in baboons: I. Aspects of hemodynamics.

Authors:  G Schlag; H Redl; S Hallström; K Radmore; J Davies
Journal:  Circ Shock       Date:  1991-07

4.  Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients.

Authors:  D Aderka; H Englemann; V Hornik; Y Skornick; Y Levo; D Wallach; G Kushtai
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701

5.  Monoclonal antibodies to soluble human TNF receptor (TNF binding protein) enhance its ability to block TNF toxicity.

Authors:  G R Adolf; B Frühbeis
Journal:  Cytokine       Date:  1992-05       Impact factor: 3.861

6.  Variation in serum levels of the soluble TNF receptors among healthy individuals.

Authors:  D Aderka; H Engelmann; Y Shemer-Avni; V Hornik; A Galil; B Sarov; D Wallach
Journal:  Lymphokine Cytokine Res       Date:  1992-06

7.  Elevated serum levels of soluble tumour necrosis factor receptors (sTNF-R) in patients with HIV infection.

Authors:  A Kalinkovich; H Engelmann; N Harpaz; R Burstein; V Barak; I Kalickman; D Wallach; Z Bentwich
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

8.  A monoclonal antibody-based enzyme immunoassay for quantitation of human tumor necrosis factor binding protein I, a soluble fragment of the 60 kDa TNF receptor, in biological fluids.

Authors:  G R Adolf; I Apfler
Journal:  J Immunol Methods       Date:  1991-09-20       Impact factor: 2.303

9.  Hyperdynamic sepsis in baboons: II. Relation of organ damage to severity of sepsis evaluated by a newly developed morphological scoring system.

Authors:  G Schlag; H Redl; C J van Vuuren; J Davies
Journal:  Circ Shock       Date:  1992-12

10.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo.

Authors:  K J Van Zee; T Kohno; E Fischer; C S Rock; L L Moldawer; S F Lowry
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

View more
  5 in total

1.  Local entrapment of interferon gamma in the recovery from Shigella dysenteriae type 1 infection.

Authors:  R Raqib; A Ljungdahl; A A Lindberg; U Andersson; J Andersson
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

2.  Protective effect of bactericidal/permeability-increasing protein (rBPI21) in baboon sepsis is related to its antibacterial, not antiendotoxin, properties.

Authors:  G Schlag; H Redl; J Davies; P Scannon
Journal:  Ann Surg       Date:  1999-02       Impact factor: 12.969

3.  Extracellular sulfatase-2 is overexpressed in rheumatoid arthritis and mediates the TNF-α-induced inflammatory activation of synovial fibroblasts.

Authors:  Ruby J Siegel; Anil K Singh; Paul M Panipinto; Farheen S Shaikh; Judy Vinh; Sang U Han; H Mark Kenney; Edward M Schwarz; Cynthia S Crowson; Sadik A Khuder; Basil S Khuder; David A Fox; Salahuddin Ahmed
Journal:  Cell Mol Immunol       Date:  2022-09-07       Impact factor: 22.096

4.  Down-regulation of gamma interferon, tumor necrosis factor type I, interleukin 1 (IL-1) type I, IL-3, IL-4, and transforming growth factor beta type I receptors at the local site during the acute phase of Shigella infection.

Authors:  R Raqib; A A Lindberg; L Björk; P K Bardhan; B Wretlind; U Andersson; J Andersson
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

5.  Sex as Biological Variable in Cardiac Mitochondrial Bioenergetic Responses to Acute Stress.

Authors:  Susan R Scott; Kanhaiya Singh; Qing Yu; Chandan K Sen; Meijing Wang
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.